We are analyzing https://link.springer.com/article/10.1007/s00280-014-2530-9.

Title:
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia | Cancer Chemotherapy and Pharmacology
Description:
Objective Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis. Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies. A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the pharmacokinetic of navitoclax as well as the time course of the platelet counts in cancer patients receiving navitoclax. Methods Data from 256 patients who received oral navitoclax (dose range 10–475 mg) as a 14/21-day schedule or a continuous once daily (QD) schedule were used to construct the model using NONMEM. The PK model was a two-compartmental model with a lag-time and a transit compartment in absorption. The PD model was a semi-physiological model that comprised a progenitor cell compartment, three transition compartments representing the maturation chain in the bone marrow and a peripheral blood compartment. Compared with the previously published models, the model established in this analysis applied a different feedback mechanism and introduced a new concept of progenitor cell “pool”, which describes a large pool of platelet progenitor cells at the beginning of navitoclax treatment. Results The PD model was able to describe a slight downward trend of platelet counts over the long-term navitoclax treatment as observed in around 8 % of the patients and the initial drop in platelets seen in our Phase 1/2a studies. Conclusions We have developed a new semi-physiological platelet model for describing fast drop of platelets after initial navitoclax administration and long-term decline of platelets after continuous administration of navitoclax.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

navitoclax, article, model, cancer, patients, study, abt, bcl, phase, pubmed, google, scholar, xiong, platelet, oncol, cas, abbvie, privacy, cookies, content, data, pharmacology, kaefer, yang, humerickhouse, family, inhibitor, cell, clin, publish, research, search, thrombocytopenia, aksana, noertersheuser, platelets, results, access, chronic, lymphocytic, leukemia, analysis, information, log, journal, pharmacokineticpharmacodynamic, published, july, jianning, peter,

Topics {✒️}

mechanism-based pharmacokinetic/pharmacodynamic meta-analysis small-cell lung cancer month download article/chapter targeted high-affinity inhibitor holland-frei cancer medicine nanoparticle albumin-bound paclitaxel primary dose-limiting toxicity phase ii open-label population pharmacokinetic/pharmacodynamic semi-mechanistic myelosuppression model semi-physiological platelet model previously untreated advanced article cancer chemotherapy chronic lymphocytic leukemia related subjects long-term navitoclax treatment full article pdf previously published models privacy choices/manage cookies bcl-2 family inhibitor chemotherapy-induced myelosuppression walid awni progenitor cell compartment progenitor cell “pool” tumour cell survival bcl-2 family proteins semi-physiological model long-term decline platelet progenitor cells dose range 10–475 mg pharmacology aims clinical pharmacology european economic area transition compartments representing slight downward trend ribeiro de oliveira conditions privacy policy peripheral blood compartment describing fast drop hao xiong phase 1/2a studies received oral navitoclax bast jr rc accepting optional cookies solid tumors friberg le induced thrombocytopenia article kaefer phase ii study distinct time profile

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
         description:Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis. Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies. A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the pharmacokinetic of navitoclax as well as the time course of the platelet counts in cancer patients receiving navitoclax. Data from 256 patients who received oral navitoclax (dose range 10–475 mg) as a 14/21-day schedule or a continuous once daily (QD) schedule were used to construct the model using NONMEM. The PK model was a two-compartmental model with a lag-time and a transit compartment in absorption. The PD model was a semi-physiological model that comprised a progenitor cell compartment, three transition compartments representing the maturation chain in the bone marrow and a peripheral blood compartment. Compared with the previously published models, the model established in this analysis applied a different feedback mechanism and introduced a new concept of progenitor cell “pool”, which describes a large pool of platelet progenitor cells at the beginning of navitoclax treatment. The PD model was able to describe a slight downward trend of platelet counts over the long-term navitoclax treatment as observed in around 8 % of the patients and the initial drop in platelets seen in our Phase 1/2a studies. We have developed a new semi-physiological platelet model for describing fast drop of platelets after initial navitoclax administration and long-term decline of platelets after continuous administration of navitoclax.
         datePublished:2014-07-23T00:00:00Z
         dateModified:2014-07-23T00:00:00Z
         pageStart:593
         pageEnd:602
         sameAs:https://doi.org/10.1007/s00280-014-2530-9
         keywords:
            Navitoclax
            ABT-263
            Pharmacokinetic
            Pharmacodynamic model
            Thrombocytopenia
            Platelet
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig4_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:74
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Aksana Kaefer
               affiliation:
                     name:AbbVie Inc.
                     address:
                        name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Jianning Yang
               affiliation:
                     name:AbbVie Inc.
                     address:
                        name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Peter Noertersheuser
               affiliation:
                     name:AbbVie Deutschland GmbH&Co.KG
                     address:
                        name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sven Mensing
               affiliation:
                     name:AbbVie Deutschland GmbH&Co.KG
                     address:
                        name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rod Humerickhouse
               affiliation:
                     name:AbbVie Inc.
                     address:
                        name:Oncology, AbbVie Inc., North Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Walid Awni
               affiliation:
                     name:AbbVie Inc.
                     address:
                        name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hao Xiong
               affiliation:
                     name:AbbVie Inc.
                     address:
                        name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
      description:Navitoclax is a first-in-class, orally bioavailable, targeted Bcl-2 family protein inhibitor and promotes apoptosis. Thrombocytopenia is a primary dose-limiting toxicity of navitoclax which exhibited a distinct time profile in circulating platelets from that caused by traditional chemotherapies. A population pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the pharmacokinetic of navitoclax as well as the time course of the platelet counts in cancer patients receiving navitoclax. Data from 256 patients who received oral navitoclax (dose range 10–475 mg) as a 14/21-day schedule or a continuous once daily (QD) schedule were used to construct the model using NONMEM. The PK model was a two-compartmental model with a lag-time and a transit compartment in absorption. The PD model was a semi-physiological model that comprised a progenitor cell compartment, three transition compartments representing the maturation chain in the bone marrow and a peripheral blood compartment. Compared with the previously published models, the model established in this analysis applied a different feedback mechanism and introduced a new concept of progenitor cell “pool”, which describes a large pool of platelet progenitor cells at the beginning of navitoclax treatment. The PD model was able to describe a slight downward trend of platelet counts over the long-term navitoclax treatment as observed in around 8 % of the patients and the initial drop in platelets seen in our Phase 1/2a studies. We have developed a new semi-physiological platelet model for describing fast drop of platelets after initial navitoclax administration and long-term decline of platelets after continuous administration of navitoclax.
      datePublished:2014-07-23T00:00:00Z
      dateModified:2014-07-23T00:00:00Z
      pageStart:593
      pageEnd:602
      sameAs:https://doi.org/10.1007/s00280-014-2530-9
      keywords:
         Navitoclax
         ABT-263
         Pharmacokinetic
         Pharmacodynamic model
         Thrombocytopenia
         Platelet
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-014-2530-9/MediaObjects/280_2014_2530_Fig4_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:74
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Aksana Kaefer
            affiliation:
                  name:AbbVie Inc.
                  address:
                     name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Jianning Yang
            affiliation:
                  name:AbbVie Inc.
                  address:
                     name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Peter Noertersheuser
            affiliation:
                  name:AbbVie Deutschland GmbH&Co.KG
                  address:
                     name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sven Mensing
            affiliation:
                  name:AbbVie Deutschland GmbH&Co.KG
                  address:
                     name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rod Humerickhouse
            affiliation:
                  name:AbbVie Inc.
                  address:
                     name:Oncology, AbbVie Inc., North Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Walid Awni
            affiliation:
                  name:AbbVie Inc.
                  address:
                     name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hao Xiong
            affiliation:
                  name:AbbVie Inc.
                  address:
                     name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:74
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:AbbVie Inc.
      address:
         name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
         type:PostalAddress
      name:AbbVie Inc.
      address:
         name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
         type:PostalAddress
      name:AbbVie Deutschland GmbH&Co.KG
      address:
         name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
         type:PostalAddress
      name:AbbVie Deutschland GmbH&Co.KG
      address:
         name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
         type:PostalAddress
      name:AbbVie Inc.
      address:
         name:Oncology, AbbVie Inc., North Chicago, USA
         type:PostalAddress
      name:AbbVie Inc.
      address:
         name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
         type:PostalAddress
      name:AbbVie Inc.
      address:
         name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Aksana Kaefer
      affiliation:
            name:AbbVie Inc.
            address:
               name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Jianning Yang
      affiliation:
            name:AbbVie Inc.
            address:
               name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
               type:PostalAddress
            type:Organization
      name:Peter Noertersheuser
      affiliation:
            name:AbbVie Deutschland GmbH&Co.KG
            address:
               name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
               type:PostalAddress
            type:Organization
      name:Sven Mensing
      affiliation:
            name:AbbVie Deutschland GmbH&Co.KG
            address:
               name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
               type:PostalAddress
            type:Organization
      name:Rod Humerickhouse
      affiliation:
            name:AbbVie Inc.
            address:
               name:Oncology, AbbVie Inc., North Chicago, USA
               type:PostalAddress
            type:Organization
      name:Walid Awni
      affiliation:
            name:AbbVie Inc.
            address:
               name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
               type:PostalAddress
            type:Organization
      name:Hao Xiong
      affiliation:
            name:AbbVie Inc.
            address:
               name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
      name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
      name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
      name:Pharmacometrics, AbbVie Deutschland GmbH&Co.KG, Ludwigshafen, Germany
      name:Oncology, AbbVie Inc., North Chicago, USA
      name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
      name:Department of Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(63)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.1s.

LINK . SPRINGER . COM {}